Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Core Insights - Quoin Pharmaceuticals has reported highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study, indicating that the treatment QRX003 has led to almost complete healing of the patient's skin after 6 weeks of application [1][2][6] - The patient has not required previously necessary medications such as antibiotics, antivirals, antihistamines, and glucocorticoids during the treatment period, and has experienced no sleep disturbances, marking a significant improvement in quality of life [2][6] - No adverse events have been reported after 6 weeks of treatment, and the company has received approval to initiate treatment on a second pediatric patient [2][6] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [5] - The company aims to address unmet medical needs and has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome [5] Product Information - QRX003 is a topical lotion designed to treat Netherton Syndrome by promoting a normalized skin-shedding process and strengthening the skin barrier [4] - The product utilizes a proprietary delivery technology and contains a broad-spectrum serine protease inhibitor, which mimics the function of the LEKTI protein absent in Netherton patients [4]